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Abstract
Hypertension and chronic kidney disease are inextricably linked. Hypertension is a well-
recognized contributor to chronic kidney disease progression and, in turn, renal disease potentiates 
hypertension. A generalized approach to drug selection and dosage has not proven effective in 
managing these conditions, in part, because patients with heterogeneous kidney disease and 
hypertension etiologies are frequently grouped according to functional or severity classifications. 
Genetic testing may serve as an important tool in the armamentarium of clinicians who embrace 
precision medicine. Increasing scientific evidence has supported the utilization of genomic 
information to select efficacious antihypertensive therapy and understand hereditary contributors 
to chronic kidney disease progression. Given the wide array of antihypertensive agents available 
and diversity of genetic renal disease predictors, a panel-based approach to genotyping may be an 
efficient and economic means of establishing an individualized blood pressure response profile for 
patients with various forms of chronic kidney disease and hypertension. In this manuscript, we 
discuss the validation process of a Clinical Laboratory Improvement Amendments (CLIA)-
approved genetic test to relay information on 72 genetic variants associated with kidney disease 
progression and hypertension therapy. These genomic-based interventions, in addition to routine 
clinical data, may help inform physicians to provide personalized therapy.
Introduction
Hypertension and chronic kidney disease are intersecting diseases with enormous economic 
burdens. The design and implementation of genotype-guided care in clinics enables 
providers to identify drug-gene interactions to inform medication selection, improve 
treatment efficacy, and reduce adverse events and their associated medical costs. Genetic 
predictors of chronic kidney disease (CKD) progression may augment standard clinical 
prediction models, impacting prognosis, medication selection, dialysis initiation, and renal 
transplant organ allocation. We have designed a genotyping test to detect 72 genetic variants 
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in drug metabolizing enzymes and other genes to aid providers in the management of 
hypertension, chronic kidney disease, and other related conditions.
This communication focuses on the analytical validity of the renal precision medicine assay, 
including CLIA validation with the assessment of precision and accuracy, analytical 
sensitivity and specificity, variant reporting strategy, and confirmation of positive reference 
materials through sequencing. Our goal is to facilitate implementation for future 
investigators and health systems. A detailed discussion of each variant’s clinical validity 
extends beyond the scope of this manuscript; however, content examples are provided in 
order to convey context and purpose.
Variant Selection
Variants in the renal precision medicine assay were selected after balancing their 
significance, effect size, minor allele frequency, and level of evidence. When applicable, 
drug-gene phenotypes were utilized from the Pharmacogene Variation Consortium 
(PharmVar), the Food and Drug Administration (FDA) drug label, Clinical 
Pharmacogenomics Implementation Consortium (CPIC) and Dutch Pharmacogenetics 
Working Group (DPWG) [1, 2]. The three groups of variants represented include predictors 
of 1) antihypertensive drug response, 2) drug response relevant to immunosuppression or 
cardiovascular disease, and 3) CKD progression. Antihypertensive pharmacogenomic 
variants were included for metoprolol (CYP2D6), other beta-blockers (GRK4, ADRB1), 
hydralazine (NAT2), losartan (CYP2C9), amlodipine (F7), thiazide diuretics (YEATS4, 
FGF5/SH2B3/EBF1), diuretics (NEDD4L), angiotensin-converting-enzyme inhibitors (F7), 
and angiotensin II receptor blockers (NPHS1) (Table 1) [3-11]. The clinical validity of these 
variants has been previously reviewed and their associated levels of evidence vary [12, 13]. 
For example, CYP2D6-guided dosing of metoprolol has been recommended by the DPWG. 
The FDA drug labels of hydralazine and losartan include NAT2 and CYP2C9 metabolizer 
status, respectively, as predictors of response. This assay employs genotype as a surrogate to 
establish metabolizer status for these drugs. Other antihypertensive response predictors 
included in the assay have lower levels of evidence for implementation. Although they have 
been replicated in clinical trials, their clinical use is still considered investigational.
A second group of pharmacogenomic variants found in the CYP3A4 and CYP3A5, TPMT, 
SLCO1B1, CYP2C9, VKORC1, and CYP2C19 genes have been widely studied with 
genotype-guided dosing recommendations from CPIC and DPWG for drugs such as 
tacrolimus, azathioprine, simvastatin, warfarin, and clopidogrel (Table 1) [14-18]. The 
immunosuppressant drug-gene pairs were selected to aid in glomerulonephritis and post-
transplant care. The cardiovascular drug-gene pairs were included due to the preponderance 
of cardiovascular disease in patients with CKD.
A third group of variants have been identified as predictors of CKD progression (Table 2) 
[19-22]. Genes associated with progression were identified from large genome-wide 
association studies or prospective clinical cohorts and trials such as the Chronic Renal 
Insufficiency Cohort and African American Study of Kidney Disease and Hypertension [20]. 
These genes include APOL1, relevant to individuals with African ancestry, as well as other 
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genes identified from African-American, Asian and Caucasian populations, with or without 
diabetes mellitus. Their clinical validity has been reviewed elsewhere [23].
Variant Reporting
When feasible, genetic nomenclature and allele reporting was utilized from PharmVar and 
CPIC. Drug-gene pairs with lower levels of evidence often lack a consensus allelic structure. 
As a result, the ADRB1, FGF5/SH2B3/EBF1, and GRK4 genes each include a multi-variant 
model to predict efficacy that is summarized by copies of amino acids or efficacy alleles. 
The APOL1 gene is comprised of the *G1 (G and GM) and *G2 variant alleles. The *G1 
allele is described as two missense variants and the *G2 allele is a 6 base pair deletion that is 
in high linkage disequilibrium with a single nucleotide polymorphism marker used in this 
assay. These variants are reported based on quantity of risk alleles. All other variants were 
classified based on the nucleotides detected. The effects of some variants were only studied 
or found to be significantly associated with phenotypes in certain populations. As such, 
some variants are only relevant in a single ethnicity or in individuals without diabetes. This 
distinction is made in the relevant population column of Table 1 and 2.
Genotyping Assay Validation
We designed a custom OpenArray in which Taqman allele discrimination was used for 
genotyping analysis for our selected variants. DNA samples were amplified in singlicate by 
real-time PCR on the LifeTech QuantStudio 12K Flex (software v1.2.2; Grand Island, NY) 
using commercially available reagents for the custom designed OpenArray according to the 
user manual (Life Technologies, Grand Island, NY). DNA samples used for analytical 
validation were obtained from the Coriell Cell Repository (Camden, NJ) and Icahn School 
of Medicine at Mount Sinai (New York, NY) [24]. In this paper, we describe the CLIA 
validation process for the variants provided in Supplemental Table 1, Supplemental Digital 
Content 1, http://links.lww.com/FPC/B331 . The CYP450s, SLCO1B1, TPMT, and 
VKORC1 variants have been previously validated as part of the INGENIOUS trial [25].
Since there were no known reference materials for most variants, selected DNA samples 
were Sanger sequenced with custom designed primers (Integrated DNA Technologies, 
Coralville, IA) for accuracy studies (Supplemental Table 1, Supplemental Digital Content 1, 
http://links.lww.com/FPC/B331). PCR amplification was performed on the GeneAmp PCR 
System 2720 (Applied Biosystems). The targeted gene region was amplified using custom 
primers and PCR SuperMix (Invitrogen, Carlsbad, CA) at the following PCR amplification 
conditions: 94°C for 2 minutes, 35 cycles at 94°C for 15 seconds, 56°C for 30 seconds, 72°C 
for 1 minute and a final extension step at 72°C for 7 minutes. PCR purification was 
performed using a QIAquick PCR Purification Kit (Qiagen, Valencia, CA) according to the 
user manual. Samples were prepared for sequencing using 10 μL of purified PCR amplicon 
(50 ng total) and 2 μL of the sequencing primer [1.7 μM] and Sanger sequenced by ACGT 
Inc. (Germantown, MD). For ADRB1, reference materials that were previously whole 
genome sequenced in the 1000 Genomes Project were obtained and genotyped. Variant 
information from the project was retrieved from https://www.ncbi.nlm.nih.gov/variation/
tools/1000genomes/ to confirm the accuracy of the ADRB1 analytical validation study.
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The sequencing results were compared to the array genotyping results and were completely 
concordant for 100% accuracy. Based on the orthogonal method (e.g. DNA sequencing), the 
variant and reference allele used to calculate the assay’s analytical sensitivity and specificity 
(Table 3 and Supplemental Table 2, Supplemental Digital Content 2, http://
links.lww.com/FPC/B332 ). The analytical sensitivity was 100% for the detection of variant 
alleles, with no reported false negatives. The analytical specificity was 100% for detection of 
reference alleles, with no false positive results reported (note at the 95th percentile, the 
confidence intervals varied based on variant frequencies). DNA samples were also used to 
assess intra- and inter-assay variation. In all, 14 samples obtained from Icahn School of 
Medicine at Mount Sinai were included in intra-assay validation. There were 18 samples 
included in the inter-assay validation which were comprised of the 14 Icahn School of 
Medicine at Mount Sinai samples plus four additional Coriell cell line samples that included 
the less frequent genotypes (NA07357, NA10847, NA18524, NA18563). In order to find 
these less frequent genotypes needed for validation, 189 total Coriell samples were 
genotyped successfully. These results are included in Supplemental Table 2 , Supplemental 
Digital Content 2, http://links.lww.com/FPC/B332, to serve as reference materials for 
laboratories that may validate the same variants. The intra- (within) assay variation studies 
showed that all three replicates of the 14 samples ran on the same plate, were concordant 
with expected results. The inter- (between) assay variation studies showed that the 18 
samples consistently yielded the same result across three separate runs. The stability had 
been previously established for the following conditions: DNA isolated from whole blood at 
room temperature after 1 week, refrigerated for 2 weeks, and frozen for 4 weeks, saliva after 
5 years at room temperature, frozen indefinitely, and extracted DNA refrigerated and frozen 
for 5 and 15 years, respectively.
Implementation
The implementation of genetic testing to aid in personalized therapy has become more 
widespread. Applications for the variants detected with this assay may extend beyond the 
clinical care of individuals with hypertension and CKD as illustrated by the implementation 
efforts of networks like the Implementing Genomics in Practice (IGNITE) and APOL1 
Long-Term Kidney Transplantation Outcomes (APOLLO) consortia. Further pragmatic 
trials are needed to determine clinical validity and utility. Understanding the underlying 
genetic architecture which predisposes an individual to develop chronic kidney disease 
allows us to build upon existing functional CKD classifications, which are presently based 
on estimate glomerular filtration rates and proteinuria. The implementation of genetic testing 
into clinical practice has the potential to augment drug selection, dose adjustment, improve 
the classification of CKD in patients, and more accurately predict the risk of progression. 
This testing serves as a complement to, not a replacement for, effective clinical practice.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1:
Efficacy and Adverse Event Phenotype-Genotype Interactions
Gene Variant Relevant
Population*
Genotyping Result Predicted Phenotype
ADRB1 rs1801252, rs1801253 0 copies of 49S-389Ra Reduced Beta-Blocker Efficacy
1 copy of 49S-389R Standard Beta Blocker Efficacy
2 copies of 49S-389R Increased Beta Blocker Efficacy
CYP2C19 rs4244285, rs4986893, 
rs28399504, rs72552267, 
rs41291556, rs6413438, 
rs12248560
*1/*1, *1/*17 Standard Clopidogrel Efficacy
*1/*2, *3, *4, *6, *8, *2/*2, 
*3, *4, *6, *8, *17b
Reduced Clopidogrel Efficacy
*17/*17 Increased Risk of Bleeding
CYP2C9 rs1799853, rs1057910, 
rs28371686, rs9332131, 
rs7900194, rs28371685
*1/*1 Standard Losartan Efficacy
*1/*2, *3, *5, *6, *8, *11b Reduced Losartan Efficacy
CYP2D6 rs16947, rs1135840, rs35742686, 
rs3892097, rs1065852, rs5030655, 
rs5030867, rs5030865(A), 
rs5030656, rs1065852, rs1135840, 
rs5030865(T), rs28371706, 
rs61736512, rs59421388, 
rs1135840, rs28371725
*1/*1, *2, *9, *10, *17, *2/
*2, *9, *10, *17, *29, *41b
Standard Metoprolol Efficacy
*1/*1xN, *1/*2xN, *2/*2xNb Reduced Metoprolol Efficacy
*1/*3, *4, *5, *6, *7, *8, 
*11, *12, *13, *14, *15, *16 
c
Increased Bradycardia with 
Metoprolol
CYP3A4 rs55785340, rs35599367 CYP3A5
*3/*3,*6,*7 b
*1/*1, *1/*22 Standard Tacrolimus Dosing
*22/*22 Reduced Tacrolimus Dosing
CYP3A5 rs776746, rs10264272, rs41303343 *3/*3, *6, *7b Standard Tacrolimus Dosing
*1/*1, *3, *6, *7 Increased Tacrolimus Dosing
F7 rs6046 African
American
G/G Standard Amlodipine Efficacy
G/A Reduced Amlodipine Efficacy
A/A Poor Amlodipine Efficacy
FGF5/ SH2B3/EBF1 rs1458038, rs3184504, rs4551053 Caucasian 0 efficacy allelesc Reduced Thiazide Efficacy
1 or 2 efficacy alleles Standard Thiazide Efficacy
3 or more efficacy alleles Increased Thiazide Efficacy
GRK4 rs2960306, rs1024323 0 copies of 65L-142Va Increased Beta-Blocker Efficacy
1 copy of 65L-142V Standard Beta Blocker Efficacy
2 copies of 65L-142V Reduced Beta Blocker Efficacy
NAT2 rs1801279, rs1801280, rs1799930, 
rs1799931
*4/*4 Standard Hydralazine Efficacy
*4/*5, *6, *7, *14b Increased Hydralazine Efficacy
NEDD4L rs4149601 Caucasian G/G Increased Diuretic Efficacy
G/A Standard Diuretic Efficacy
A/A Reduced Diuretic Efficacy
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Gene Variant Relevant
Population*
Genotyping Result Predicted Phenotype
NPHS1 rs3814995 Caucasian G/G Standard ARB Efficacy
G/A or A/A Increased ARB Efficacy
SLCO1B1 rs4149056, rs4149015 *1/*1, *1/*21, *21/*21 Standard Simvastatin Dosing
*1/*5, *1/*17, *5/*5, Reduced Simvastatin Dosing
*5/*17, *17/*17, *17/*21 Reduced Simvastatin Dosing
TPMT rs1800462, rs1800460 and 
rs1142345, rs1800460, rs1142345, 
rs1800584
*1/*1 Standard Azathioprine Dosing
*1/*2, *1/*3, *2/*2, *2/*3, 
*3/*3
Reduced Azathioprine Dosing
Reduced Azathioprine Dosing
VASP rs10995 Caucasian A/A Standard Thiazide Efficacy
A/G or G/G Increased Thiazide Efficacy
VKORC1 rs9923231 G/G Standard Warfarin Sensitivity
G/A or A/A Increased Warfarin Sensitivity
YEATS4 rs7297610 African
American
T/T or T/C C/C Standard Thiazide Efficacy
C/C Increased Thiazide Efficacy
*
Relevant population provided if results have only been identified in a specific population.
a2-variant model summarized by the number of copies of the amino acid pairs.
bAn abbreviated list is provided due to the large number of possible genotyping results.
c3-variant model summarized by the number of efficacy alleles. Efficacy alleles are as follows: rs1458038 (C), rs3184504 (C), rs4551053 (G)
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Table 2:
Genotype-Predicted Risks for Chronic Kidney Disease Progression
Gene Variant Relevant
Population*
Genotyping Result Predicted CKD
Progression Risk
APOL1 rs73885319, rs60910145, rs71785313 African American 0 or 1 risk allelea Standard Risk
2 or more risk alleles Increased Risk
LINC00923 rs653747 African American
non-diabetic
C/C Standard Risk
C/T or T/T Increased Risk
SHROOM3 rs17319721 Caucasian G/G Standard Risk
G/A or A/A Increased Risk
SHROOM3 rs4371638 African American C/C Standard Risk
C/T or T/T Increased Risk
SHROOM3 rs13146355 Asian G/G Standard Risk
G/A or A/A Increased Risk
SLC3A2 rs489381 Caucasian C/C Standard Risk
C/A or A/A Increased Risk
SLC3A2/LOC105369332 rs2282538 African American G/G Standard Risk
G/A or A/A Increased Risk
UMOD rs4293393 African American T/T or T/C Standard Risk
C/C Reduced Risk
UMOD rs12917707 Caucasian C/C or C/A Standard Risk
A/A Reduced Risk
UMOD/PDILT rs11864909 Asian G/G or G/A Standard Risk
A/A Reduced Risk
*
Relevant population provided if results have only been identified in a specific population.
a3-variant model summarized by the number of risk alleles, * G1(G), * G1(GM), and* G2.
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Table 3:
Analytical Sensitivity, Specificity, and Accuracy of OpenArray
Gene Variant AnalyticalSensitivity
Analytical
Specificity Accuracy
ADRB1
c.1165G>C (rs1801253)
100% (95% CI; 93-100) 100% (95% CI; 98-100) 100%
c.145A>G (rs1801252)
APOL1
c.1072A>G (rs73885319)
100% (95% CI; 91-100) 100% (95% CI; 98-100) 100%c.1200T>G (rs60910145)
c.1212_1217delTTATAA (rs71785313)
EBF1 g.158411534G>A (rs4551053) 100% (95% CI; 57-100) 100% (95% CI; 74-100) 100%
FGF5 g.81164723C>T (rs1458038) 100% (95% CI; 51-100) 100% (95% CI; 61-100) 100%
GRK4
c.194G>T (rs2960306)
100% (95% CI: 82-100) 100% (95% CI; 85-100) 100%
c.329C>T (rs1024323)
LINC00923 g.97659878C>T (rs653747) 100% (95% CI; 79-100) 100% (95% CI; 72-100) 100%
NAT2
c.857G>A (rs1799931)
100% (95% CI; 97-100) 100% (95% CI; 95-100) 100%
c.191G>A (rs1801279)
c.590G>A (rs1799930)
c.341T>C (rs1801280)
NEDD4L c.24G>A (rs4149601) 100% (95% CI; 57-100) 100% (95% CI; 83-100) 100%
NPHS1 g.35851310C>T (rs3814995) 100% (95% CI; 65-100) 100% (95% CI; 65-100) 100%
SHROOM3
c.168+11474G>A (rs17319721)
100% (95% CI; 57-100) 100% (95% CI; 65-100) 100%c.169-36495T>C (rs4371638)
c.168+54767G>A (rs13146355)
SH2B3 c.784T>C (rs3184504) 100% (95% CI; 61-100) 100% (95% CI; 72-100) 100%
SLC3A2 c.1066-41A>G (rs489381) 100% (95% CI; 77-100) 100% (95% CI; 72-100) 100%
SLC3A2/LOC105369332 g.62832260C>T (rs2282538) 100% (95% CI; 34-100) 100% (95% CI; 84-100) 100%
UMOD
c-680T>C (rs4293393)
100% (95% CI; 68-100) 100% (95% CI; 90-100) 100%
c.−214C>A (rs12917707)
UMOD/PDILT c.203-4666G>A (rs11864909) 100% (95% CI; 34-100) 100% (95% CI; 85-100) 100%
VASP c.*719G>A (rs10995) 100% (95% CI; 70-100) 100% (95% CI; 57-100) 100%
YEATS4 g.69430244C>T (rs7297610) 100% (95% CI; 34-100) 100% (95% CI; 85-100) 100%
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